Targeted-release budesonide for patients with IgA nephropathy
<b>Commentary on:</b> Lafayette R, Kristensen J, Stone A, <i>et al</i> Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. <i>Lancet</i> 2023;402:859-70.<b>Series co-ordinator:</b> Dr Teck Khong, DTB Associate Editor, Clinical Pharmacology, St George's, University of London, UK.
Authors
- Isaac Chung (ORCID: https://orcid.org/0000-0002-1517-4359)
- Teck K Khong (ORCID: https://orcid.org/0000-0001-9873-1204)
Institutions
- St George's, University of London (GB)
- St George’s University Hospitals NHS Foundation Trust (GB)
Publication Details
- Journal
- Drug and Therapeutics Bulletin
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1136/dtb.2024.000071
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00